Global Heparin Sodium Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Heparin Sodium Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Heparin Sodium is formed by a heterogeneous group of straight-chain anionic mucopolysaccharides called glycosaminoglycan. It can be described as a glycosaminoglycan sulfate. Heparin delays the coagulation of fresh blood.

Heparin is strongly acidic because of its content of covalently linked sulfate and carboxylic acid groups. In heparin sodium, the acidic protons of the sulfate units are partially replaced by sodium ions.

Market Overview:

The latest research study on the global Heparin Sodium market finds that the global Heparin Sodium market reached a value of USD 4156.97 million in 2022. It’s expected that the market will achieve USD 6397.58 million by 2028, exhibiting a CAGR of 7.45% during the forecast period.

Influence of COVID-19 Outbreak on Heparin Sodium Industry Development

COVID-19 can lead to the risk of thrombosis. The current US authority recommends the use of low molecular weight heparin for prevention and treatment,which increases the demand for low molecular weight heparin. Clinical trials for the treatment of COVID-19 patients in many countries have found that multiple COVID-19 patients have concurrent venous thromboembolism (VTI), especially with pulmonary embolism (PE), which may cause the infection to worsen, And even an important cause of death. In addition, some patients have obvious hypercoagulability in the early stage, and extensive micro thrombosis may be secondary to them without intervention.
Because the medical community in many countries and regions has issued guidelines for the application of low-molecular-weight liver blood tests for prevention. The American Society of Hematology (ASH) and the International Society of Thrombosis and Hemostasis (ISTH) both recommend that the COVID-19 patients should receive low-molecular-weight heparin sodium injections to prevent thrombosis if there are no contraindications.
After the epidemic is over, the people will have higher demand for health management and health care, which will promote the growth of medical consumption expenditure. Driven by this factor, more new entrants will enter the pharmaceutical industry, which will promote the research of drugs and reagents in the pharmaceutical industry.

Limitations

Upstream raw material supply and price fluctuation risk
After industry competition over the past five years, a large number of small and medium-sized enterprises have withdrawn from the industry. In the future, industry competition will enter the field of refined competition, which requires major players in the industry to invest more in technology research and development, energy conservation and environmental protection investment, cost control, and marketing expansion to win more industry status for themselves.
Affected by African swine fever in 2019, the slaughter of live pigs has fallen sharply. Due to the relatively high utilization rate of pig intestines, large-scale alternative raw material sources cannot be found in the short term. Therefore, the market is in short supply. It should be soberly recognized that there is a cyclic phenomenon in the pig breeding industry, and its main demand is the demand for protein meat, and the demand for crude heparin only accounts for a small part. Therefore, it is foreseeable that this raw material supply-side risk may still break out in the future, so the main participants in the crude heparin market may consider establishing a raw material strategic inventory and expanding exclusive supply systems to avoid this risk.

Strict government regulation

In Europe and North America, the largest consumer region of heparin sodium, there are strict regulatory systems for drugs. Regulatory agencies such as Food and Drug Administration and European Medicines Agency have very strict approvals for heparin sodium products. A large number of companies in the industry have also received strict supervision. This will reduce the number of new entrants in the industry and is also one of the most important factors restricting the development of the industry.

National medical expenditure growth slows

Europe is the most important consumer market for heparin sodium products, but the growth rate of medical expenditure in several major European countries has slowed down significantly. Taking UK as an example, UK health spending has grown by 1.6% a year over the last 4 years. This is much less than half the historical average growth rate. Compared to similar countries, the UK's day-to-day spending on health is around average, but the capital investment is notably low. This will obviously limit the development of the heparin sodium industry.

Region Overview:

Europe had the highest growth rate of all regions.

Company Overview

Sanofi is one of the major players operating in the Heparin Sodium market, holding a share of 41.12% in 2020.

Sanofi operates as a pharmaceutical company. The Company manufactures prescription pharmaceuticals and vaccines. Sanofi also develops cardiovascular, thrombosis, metabolic disorder, central nervous system, and oncology medicines and drugs. Sanofi serves customers worldwide.

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent protected prescription medicine and generic pharmaceuticals and biosimilars.

Segmentation Overview:

Among different product types, Injection Type segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Cardioversion of Atrial Fibrillation/Flutter segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Heparin Sodium market covered in Chapter 3:

Pfizer
Sanofi
Nanjing King-Friend
Amphastar Pharmaceuticals
Aspen Pharmacare
Novartis
Shenzhen Hepalink
LEO Pharma
Qianhong Bio-pharma

In Chapter 4 and Chapter 14.2, on the basis of types, the Heparin Sodium market from 2018 to 2029 is primarily split into:

Oral Type
Injection Type

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Heparin Sodium market from 2018 to 2029 covers:

Treatment of Venous Thromboembolism
Complications of Pregnancy
Cardioversion of Atrial Fibrillation/Flutter
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)